CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx
This article was originally published in The Pink Sheet Daily
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
You may also be interested in...
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.
Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.